Friday, August 29, 2014

OTC Derivatives: Clearing, Reporting and Collateral Management Workshop

Maroon's Ben Watson, a highly-regarded expert on OIS in the Asia-Pacific region, recently concluded a well-received presentation on "Managing Capital and Liquidity Impacts on Collateral Management" at the Risk Australia Workshop on OTC Derivatives in Sydney which was held on the 12th and 13th of August. The presentation touched upon the strategies in which banks can maximize capital efficiency and liquidity mobility especially in an ever-changing compliance and market environment as well as the strategies to enhance operational efficiency and to reduce risk through portfolio compression.

For interested parties, the slides from the presentation can be found here.

Tuesday, August 12, 2014

Consultation Paper on Proposals to Enhance Regulatory Safeguards for Investors in Capital Markets

The Monetary Authority of Singapore (‘MAS’) has released a consultation on proposals to enhance regulatory safeguards for investors in capital markets with three major drives. First, MAS proposes to extend the regulatory safeguards to retail investors to non-conventional products that are similar to regulated capital markets products: Buy-back arrangements involving precious metals are proposed to be considered debentures. The scope of collective investment schemes (‘CIS’) is proposed to be extended to products that do not pool contributions but assets are managed as a whole and thus pooled in effect.

Friday, August 1, 2014

MAS Consultation Paper on Proposed Amendments to AML/CFT Notices

The Monetary Authority of Singapore (‘MAS’) has released a consultation paper on proposed amendments to its Notices to Financial Institutions (‘FIs’) on Anti-Money Laundering and Countering the Financing of Terrorism (‘AML/CFT Notices’).

Adding greater emphasis to a risk-based approach (‘RBA’), capital markets intermediaries (‘CMIs’) will be required to perform a general risk assessment regarding their money laundering and terrorism financing risk. A similar risk assessment must be performed for new products, new business practices and the use of new technologies.